Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers
Preliminary Phase 1b data is in line with Phase 1a data reported at the European Society of Medical Oncology in...
Pharmaceutical
Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers
Preliminary Phase 1b data is in line with Phase 1a data reported at the European Society of Medical Oncology in...
CNS Pharmaceuticals Announces CEO Transition
Industry veteran Rami Levin, MBA appointed as President & Chief Executive Officer HOUSTON, TX / ACCESS Newswire / December 17,...
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer,...
Addition Therapeutics Announces $100 Million in Funding and Significant Progress Advancing Mission to Fulfill Promise of Genomic Medicine for Chronic and Rare Diseases
All-RNA, non-viral, LNP-based PRINT™ platform is designed to develop safer, durable, one-time therapies for a broad range of unmet needsAddition...
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative...
Secura Bio Announces NCCN® Duvelisib (COPIKTRA®) Update to Clinical Practice Guidelines in Oncology for Cutaneous T-Cell Lymphoma (CTCL), Including Mycosis Fungoides and Sézary Syndrome
BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes...
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program
License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI...
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference
SAN CARLOS, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity...
Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease
NESS ZIONA, Israel, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients...
Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress
-- Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in...
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
Ratutrelvir shows a differentiated profile versus PAXLOVID™ with fewer adverse events and no viral rebounds Activity shown in Paxlovid®-ineligible patients,...
Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California
VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”),...
Heidi Hunter Appointed New Vice Chair of the Board of Directors of Bavarian Nordic
COPENHAGEN, Denmark, December 17, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that, following the recent appointment of Anne...
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or...
Biologics X 3DCC Conference 2026: Merging Innovation, Drug Development, and Translation for the Next Era of Biopharma
Registrations OPEN India's first of-its-kind, 6th Annual Summit on Biopharmaceutical Product Development in conjunction with the 3rd edition of the International Conference...
Biologics X 3DCC Conference 2026: Merging Innovation, Drug Development, and Translation for the Next Era of Biopharma
Registrations OPEN India's first of-its-kind, 6th Annual Summit on Biopharmaceutical Product Development in conjunction with the 3rd edition of the International Conference...
Bioz Automation Delivers Seamless, Up-to-Date Publication Evidence Across DECTRIS Technologies
PALO ALTO, CALIFORNIA / ACCESS Newswire / December 17, 2025 / Bioz, Inc., the leading AI-powered platform that transforms published...
Bioz Automation Delivers Seamless, Up-to-Date Publication Evidence Across DECTRIS Technologies
PALO ALTO, CALIFORNIA / ACCESS Newswire / December 17, 2025 / Bioz, Inc., the leading AI-powered platform that transforms published...
Bioz Automation Delivers Seamless, Up-to-Date Publication Evidence Across DECTRIS Technologies
PALO ALTO, CALIFORNIA / ACCESS Newswire / December 17, 2025 / Bioz, Inc., the leading AI-powered platform that transforms published...